Skip to main content
Top
Published in: Inflammation 6/2003

01-12-2003

Syntheses of Prostaglandin E2 and E-Cadherin and Gene Expression of β-defensin-2 by Human Gingival Epithelial Cells in Response to Actinobacillus actinomycetemcomitans

Authors: Takuji Noguchi, Hideki Shiba, Hitoshi Komatsuzawa, Noriyoshi Mizuno, Yuushi Uchida, Kazuhisa Ouhara, Ryuji Asakawa, Seiji Kudo, Hiroyuki Kawaguchi, Motoyuki Sugai, Hidemi Kurihara

Published in: Inflammation | Issue 6/2003

Login to get access
Metadata
Title
Syntheses of Prostaglandin E2 and E-Cadherin and Gene Expression of β-defensin-2 by Human Gingival Epithelial Cells in Response to Actinobacillus actinomycetemcomitans
Authors
Takuji Noguchi
Hideki Shiba
Hitoshi Komatsuzawa
Noriyoshi Mizuno
Yuushi Uchida
Kazuhisa Ouhara
Ryuji Asakawa
Seiji Kudo
Hiroyuki Kawaguchi
Motoyuki Sugai
Hidemi Kurihara
Publication date
01-12-2003
Publisher
Kluwer Academic Publishers-Plenum Publishers
Published in
Inflammation / Issue 6/2003
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1023/B:IFLA.0000006702.27906.e9

Other articles of this Issue 6/2003

Inflammation 6/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine